Director @ The Clem Jones Centre for Ageing Dementia Research, Australia
Since 2012, Jürgen Götz is Foundation Chair of Dementia Research and Director of the Clem Jones Centre for Ageing Dementia Research at the Queensland Brain Institute (University of Queensland). After undergraduate studies at the Biocenter of the University of Basel, Jürgen Götz joined the laboratory of Nobel Laureate Georges Köhler to obtain his PhD degree in immunology. Subsequently, he took up postdoctoral positions at UCSF (San Francisco) and Sandoz Ltd (now Novartis, Basel). In 1994 he became a Research Group Leader at the University of Zurich (Switzerland). In 2005, he relocated to Australia to become Professor and Chair of Molecular Biology at the University of Sydney. Götz is an internationally renowned expert in basic research on Alzheimer’s disease (AD). He generated the first tau transgenic mouse model with an early AD phenotype. He provided evidence for the amyloid cascade hypothesis (Science, >1,200 cit.) and this highly cited work was accompanied by an Editorial in the same issue of Science. He further identified a novel function of tau in mediating Aβ toxicity (Cell), causing a paradigm shift. More recently, he developed a novel non-pharmacological treatment of amyloid-depositing mice using scanning ultrasound that restored memory functions in these mice (Science Translational Medicine). Jürgen Götz has also authored several highly cited review articles in journals such as Nature Reviews Neuroscience (2), Nature Reviews Neuroloy (2), Lancet, Trends in Cell Biology, Trends in Neurosciences, Trends in Molecular Medicine, Brain Research Reviews, Molecular Psychiatry and Progress in Neurobiology (3). With an H-index of 58, Jürgen Götz has published more than 160 peer-reviewed articles, and his publications have been collectively cited around 13,000 times (Google Scholar).